★
Trade Filings
Manajer Saham Pengajuan Superinvestor
Sinyal Pembelian Institusional Penjualan Institusional Aktivitas Orang Dalam 13D & 13G Watch Rotasi Sektor
Alat Penyaring Saham Penyaring Manajer Bandingkan Manajer Keranjang Konsensus Semua Alat Riset API Data
Pelajari & AI Pelajari Tanya Data AI Agents
Berita ★ Tersimpan
Tentang Tentang kami Metodologi Kontak Penafian
Pembaca
PAKET DATA

Unduhan data historis — akan hadir bersama akun.

API GATEWAY

Akses JSON baca-saja gratis ke data yang disimpan dalam cache situs.
Mode gelap

🧭 Tampilan Terpandu
Baru mengenal pasar — harga, yield, YTD, kapitalisasi pasar? Kami menjelaskan setiap istilah saat Anda menjelajah, dalam bahasa yang mudah dipahami. Data yang sama, dengan panduan yang sudah terintegrasi.

⚡ Pandangan Ahli
Anda sudah memahami pasar. Hanya data — bersih, cepat, dan ringkas, tanpa penjelasan tambahan. Ini adalah tampilan default.

Bahasa antarmuka
Catatan efek · kuartal yang diarsipkan

LLY

Eli Lilly and Company · Healthcare · Drug Manufacturers - General

1,233.5 -1.1% kapitalisasi pasar $1.16T kuotasi tertunda (FMP) · per Aug 25 22:08 UTC — terpisah dari data pengajuan di bawah

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
193Pemegang yang dilacak
+2Δ pemegang
707.04MSaham yang dipegang
$758.81BNilai yang dilaporkan
+3Posisi baru
−0Keluar
Stable Skor keyakinan 55/100 3 kuartal dengan peningkatan saham yang dilacak ●●●○○○ Cara penghitungan ini dilakukan → Jelaskan ini di Meja Riset →

Input momentum (manajer yang sebanding): keluasan pemegang +1.0% · aliran saham -0.6% · posisi baru bersih +1.6% — formula
Fragmentasi kepemilikan — lebih banyak pemegang, agregat kepemilikan lebih kecil

Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q4 2025

Kepemilikan dari waktu ke waktu
KuartalPemegangΔSahamNilai yang dilaporkanBaruKeluar
Q2 2026 193 +4 671.92M $804.91B +6 −1
Q1 2026 191 -3 666.59M $613.20B +1 −5
Q4 2025 193 +2 707.04M $758.81B +3 —
Q3 2025 27 -3 329.88M $251.63B +2 −6
Q2 2025 28 -1 307.45M $239.60B +2 −3
Q1 2025 26 0 140.32M $115.83B +1 −1
Q4 2024 26 +1 145.00M $111.91B +3 −2
Q3 2024 24 +2 109.89M $97.29B +2 —
Q2 2024 22 — 112.43M $101.75B — —
Jumlah pemegang
Siapa yang memegangnya · Q4 2025
#ManajerSahamΔ sahamNilaiBobotnyaDipegang
1 Lilly Endowment Inc 92.19M — $99.08B 100.0% n/c 1 SEC ↗
2 The Vanguard Group ✦ (pasif) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
3 The Vanguard Group ✦ (pasif) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
4 The Vanguard Group ✦ (pasif) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
5 The Vanguard Group ✦ (pasif) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
6 The Vanguard Group ✦ (pasif) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
7 The Vanguard Group ✦ (pasif) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
8 The Vanguard Group ✦ (pasif) 81.97M +1.2% $88.09B 1.3% ▲ Add 3 SEC ↗
9 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
10 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
11 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
12 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
13 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
14 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
15 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
16 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
17 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
18 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
19 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
20 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
21 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
22 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
23 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
24 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
25 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
26 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
27 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
28 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
29 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
30 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
31 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
32 BlackRock ✦ (pasif) 66.79M +1.5% $71.78B 1.2% ▲ Add 3 SEC ↗
33 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
34 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
35 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
36 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
37 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
38 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
39 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
40 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
41 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
42 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
43 Pnc Financial Services Group, Inc. 51.33M — $55.17B 30.1% n/c 1 SEC ↗
44 State Street Global Advisors ✦ (pasif) 35.36M +1.8% $38.00B 1.3% ▲ Add 5 SEC ↗
45 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
46 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
47 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
48 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
49 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
50 Fidelity (FMR) ✦ 25.72M +6.4% $27.64B 1.4% ▲ Add 3 SEC ↗
51 Capital Research Global Investors 24.57M — $26.40B 4.9% n/c 1 SEC ↗
52 Geode Capital Management ✦ (pasif) 19.81M 0.0% $21.22B 1.3% ▼ Trim 7 SEC ↗
53 Geode Capital Management ✦ (pasif) 19.81M 0.0% $21.22B 1.3% ▼ Trim 7 SEC ↗
54 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
55 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
56 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
57 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
58 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
59 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
60 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
61 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
62 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
63 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
64 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
65 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
66 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
67 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
68 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
69 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
70 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
71 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
72 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
73 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
74 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
75 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
76 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
77 Morgan Stanley ✦ 15.59M +2.7% $16.76B 1.0% ▲ Add 2 SEC ↗
78 Capital World Investors ✦ 15.03M +0.4% $16.15B 2.2% ▲ Add 7 SEC ↗
79 T. Rowe Price ✦ 14.91M +10.6% $16.02B 1.7% ▲ Add 7 SEC ↗
80 T. Rowe Price ✦ 14.91M +10.6% $16.02B 1.7% ▲ Add 7 SEC ↗
81 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
82 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
83 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
84 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
85 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
86 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
87 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
88 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
89 Wellington Management ✦ 13.36M -8.3% $14.35B 2.5% ▼ Trim 7 SEC ↗
90 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
91 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
92 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
93 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
94 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
95 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
96 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
97 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
98 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
99 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗
100 JPMorgan Chase ✦ 13.00M -36.7% $13.97B 0.9% ▼ Trim 2 SEC ↗

"Bobot mereka" = porsi posisi dari total nilai ekuitas 13F yang dilaporkan manajer tersebut — ukuran keyakinan. ✦ = manajer yang dikurasi.

Pembeli baru

Tidak ada pembeli terlacak baru kuartal ini.

Telah keluar

Tidak ada keluar yang terlacak kuartal ini.

Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 4,323 pemegang, 762.84M saham, $674.93B dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.

Sering dimiliki bersama

Apa lagi yang paling sering dimiliki oleh pemegang efek ini yang dilacak — berdasarkan jumlah kepemilikan bersama, bukan hubungan fundamental.

AMZN191pemegang bersama MSFT190pemegang bersama GOOGL189pemegang bersama NVDA187pemegang bersama META187pemegang bersama
Transaksi orang dalam

Pembelian di pasar terbuka (P)

Tidak ada pembelian insider di pasar terbuka dalam jendela cakupan kami.

Penjualan di pasar terbuka (S)

Aug 17 Jonsson Patrik

Officer · 6.50K lbr · $7.64M

Aug 10 Zakrowski Donald A

Officer · 2.00K lbr · $2.37M

Aug 07 Hakim Anat

Officer · 5.00K lbr · $5.95M

Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi

Kepemilikan manfaat
Jul 23 SC 13G/A — LILLY ENDOWMENT INC

Lihat pengajuan SEC asli ↗
Dalam berita
Aug 24 FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test ↗

The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…

 Forbes
Aug 24 FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly ↗

The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…

 WSJ
Aug 24 Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance ↗

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help ​identify signs of…

 Reuters
Aug 24 Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. ↗

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…

 WSJ
Aug 23 Eli Lilly launches oral weight-loss pill Foundayo in UK ↗

Eli Lilly said on Monday it has launched its oral pill, ​Foundayo, in the UK for weight ‌management and type 2…

 Reuters
Asal-usul data: Kepemilikan dari posisi saham biasa 13F yang telah diurai (semesta yang dipantau, set pembanding untuk perubahan); baris orang dalam dari Formulir 3/4/5; kepemilikan saham signifikan dari Jadwal 13D/13G; setiap pengajuan tertaut ke dokumen aslinya di SEC EDGAR. Periode pelaporan: Q4 2025 · Metodologi · Dapatkan ini melalui API